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Background/Objective: Insulin degludec (IDeg) is an ultra-long-acting analog with less
daily variability compared to other basal insulins. In this retrospective study we examined
1-year efficacy and safety of IDeg in youth with type 1 diabetes (T1D).
Subjects/Methods: Thirty-seven patients [11.7 ± 4.22 years; T1D duration 4.97
± 3.63 years; once-daily glargine (IGlar) by at least 1 year] were switched to once-daily
IDeg because of glycosylated hemoglobin (HbA1c)>7.5% and/or reported physical pain
at IGlar injection. Changes in HbA1c, 30-day mean fasting plasma glucose (mean FPG),
daily insulin dose, and severe hypoglycemia rates were collected at basal insulin switch
(T0), 3-months (T1), 6-months (T2), and 12-months (T3) after IDeg was started.
Results: In patients with HbA1c>7.5% at T0 we found a decrease in HbA1c values (%)
from 8.46 ± 0.53 to 7.89 ± 0.72 at T1 (p = 0.008) and 7.97 ± 0.89 at T2 (p = 0.035).
At T3, 38.9% of patients had HbA1c ≤7.5%. Mean FPG levels significantly decreased at
T2 (p= 0.043). In the overall study population, we documented an increase in IDeg dose
(+12.5% at T3; p < 0.001) and a decrease in mealtime insulin dose (−11.6% at T3; p =
0.001) after switch. HbA1c levels were unchanged. No episode of severe hypoglycemia
was reported.
Conclusions: Our data in children and adolescents with T1D suggest that IDeg dose
should be increased by 12% and mealtime insulin doses should be lowered by 11% for
patients who previously received IGlar. IDegmight be considered useful and well tolerated
and it seems to improve the glycemic control compared to IGlar, mainly in patients with
poor glycemic control.
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INTRODUCTION
Type 1 diabetes (T1D) is the most common endocrine chronic
disease in pediatrics and its incidence in Italy shows a linear
increasing temporal trend with an annual increment of 2.94%
(1). T1D management is yet difficult despite new insulins and
advanced technologies.
The Diabetes Control and Complications Trial (2) and
its follow-up Epidemiology of Diabetes Interventions and
Complications study (3, 4) demonstrated that a good glycemic
control can reduce the risk to develop both short- and long-
term complications and delay the progression of existing
complications in T1D.
In order to optimize the therapeutic management in both
children and adolescents, specific guidelines were published by
the International Society for Pediatric and Adolescent Diabetes
(ISPAD) (5, 6) and the American Diabetes Association (ADA)
(7). Basal-bolus intensive treatment with analogs was established
as a mainstay of care for all patients with T1D.
Severe hypoglycemia remains a challenge for patients with
T1D across their life span and its rates increase with lower
glycosylated hemoglobin (HbA1c) levels (8). Parents’ and/or
patients’ fear of severe hypoglycemia is the main barrier to
achieve good glycemic control (9) with subsequently increased
risk for diabetic ketoacidosis and long-term complications (10).
Advances in basal insulin therapy came with long-acting
analogs glargine (IGlar) and detemir. They represented an
improvement over intermediate-acting neutral protamine
Hagedorn, but there may still be inter- and intra-individual
glucose-lowering effect variability from injection to injection
which may consequently have an impact on the risk of both
hyper- and hypoglycemia (11, 12). Approximately 70-80% of
patients using IGlar need a once-daily injection, whereas others
require twice-daily injections to cover their 24 h basal insulin
supplementation. These latter patients were demonstrated to
need a higher dose of insulin to attain optimal glycemic targets
and to experience more frequent episodes of hypoglycemia (13).
Degludec (IDeg) is a new, ultra-long-acting form of insulin,
developed for once-daily administration. After subcutaneous
administration, IDeg forms long chains of multi-hexamers from
which monomers are slowly and continuously released and
gradually absorbed into the circulation (14). Due to its unique
mechanism of protracted and constant absorption rate, the mean
terminal half-life of IDeg exceeds 25 h with a duration of action
exceeding 42 h allowing, at steady-state, a lower within-patient
day-to-day variability (15). The reproducible pharmacodynamic
profile of IDeg allowed an improvement of HbA1c (16), a flat
and stable glucose-lowering profile (16–20), a lower risk of
Abbreviations: ADA, American Diabetes Association; BMI, Body mass index;
FPG, Fasting plasma glucose; HbA1c, Glycosylated hemoglobin; IDeg, Insulin
degludec; IGlar, Insulin glargine; ISPAD, International Society for Pediatric and
Adolescent Diabetes; IU, International unit; MT, Mealtime; n, Number; SD,
Standard deviation; SDS, Standard deviation score; SE, Standard error; SMBG,
Self-monitoring of blood glucose; T0, Switch basal insulin time; T1, 3 months
after insulin switch; T2, 6 months after insulin switch; T3, 12 months after insulin
switch; T1D, Type 1 diabetes; TDD, Total daily dose; –, Not determined; =, The
same.
hypoglycemia (16, 18, 21–25), and greater treatment satisfaction
(26) with respect to IGlar. The switch from IGlar to once-
daily IDeg also led to significant decrease in insulin total daily
dose (TDD) because of reduction in long-acting analog and/or
rapid-acting analog doses (16, 19, 23, 27–30).
The ultra-long pharmacokinetic profile of IDeg seen in
adults was demonstrated also in children and adolescents with
T1D (31–33) and there is great interest in studies testing whether
evidence collected from randomized controlled trials translates
into the real world. Our preliminary data in children and
adolescents with T1D demonstrated that the switch from IGlar
to IDeg allowed a significant reduction in insulin TDD due to a
reduction in both basal insulin and rapid-acting analog/regular
insulin doses at mealtime (MT). Despite the lack of statistical
significance, mean HbA1c was decreased by 0.2% point and
fasting plasma glucose (FPG) was improved by 9.5%. Body mass
index (BMI) z-score did not change and no episode of severe
hypoglycemia was reported (34, 35).
We performed this retrospective study wherein children and
adolescents with T1D on once-daily IGlar were studied before
and after switching to once-daily IDeg, to evaluate its 1-year
efficacy and safety.
MATERIALS AND METHODS
Patients and Study Design
This was a 1-year, retrospective, non-randomized, and single-arm
study. Subjects were enrolled among children and adolescents
with T1D followed at the Pediatric Diabetes Clinic of the
University of Modena and Reggio Emilia between November
2015 and July 2016. The switch from once-daily IGlar (Lantus R©
100 Units/mL, Sanofi, Paris, France) to once-daily IDeg
(Tresiba R©100 Units/mL, Novo Nordisk, Bagsvard, Denmark),
was suggested by pediatric diabetologist because of HbA1c
>7.5% (>58 mmol/mol) and/or self-reported physical pain at
IGlar injection. Inclusion criteria were: age 3–18 years, diagnosis
of T1D (36) at least 1 year prior to the study, and treatment
for at least 1 year with basal-bolus insulin injections with IGlar
as the basal insulin and rapid-acting analog and/or regular
insulin as the bolus insulin. Exclusion criteria were: other types
of diabetes, the presence of other autoimmune diseases and/or
chronic complications, concomitant oral antidiabetic drugs, the
presence of antibodies to insulin. Moreover, considering that the
insulin requirement increases during pubertal development (6),
patients with early puberty (Tanner stage 2) and mid puberty
(Tanner stage 3) were excluded to avoid influences on results.
Each patient was used as his/her own control and none
dropped out during the 1-year study period.
Primary efficacy objectives were the detection of significant
changes in (1) glycemic control indexes and (2) insulin TDD
and number of insulin injections. Secondary objectives were
the evaluation of tolerability and safety, including severe
hypoglycemic episodes, adverse events, and auxological data.
This study was carried out in accordance with the
recommendations of Ethics Committee of the University
of Modena and Reggio Emilia. The protocol was approved
by the Ethics Committee of the University of Modena and
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Reggio Emilia (Protocol Number 149/15). All subjects gave
written informed consent in accordance with the Declaration of
Helsinki.
Outcome Variables
Information on HbA1c, FPG, insulin TDD, and number of
injections, severe hypoglycemia rates, and BMI z-score was
collected at baseline in the day of basal insulin switch (IGlarT0
and IDeg T0), 3-months (T1), 6-months (T2), and 12-months
(T3) after IDeg was started.
HbA1c was measured at each visit and it was assayed using
a validated high-performance liquid chromatography analyzer
(Arkray Adams HA-8160; Menarini diagnostics; Florence, Italy).
HbA1c target <7.5% (<58 mmol/mol) was used to define an
optimal level of control (7, 37).
Mean FPG values were calculated using the last 30 days
self-monitoring of blood glucose (SMBG) profiles recorded by
glucometer whose data were daily registered on glycemic diary by
all patients/parents and downloaded via Diasend R©when possible.
All patients checked their blood glucose levels at least four
times/day: before breakfast, lunch, dinner, and at bedtime as well
as when experiencing symptoms of hypoglycemia. No one used
a continuous glucose monitoring system during the entire study
period.
Data of insulin doses were analyzed considering insulin TDD,
basal long-acting analog (IGlar and IDeg), and bolus insulin
(rapid-acting analog and/or regular) atMT; they were reported as
units (IU) per kg body weight per day. Basal-bolus insulin doses
were individually adjusted by the pediatric diabetologist at clinic
visit or during a telephone contact, according to SMBG values.
In each patient the type of MT insulin preparation was never
changed throughout the study period.
The number of daily insulin injections was considered at
baseline and at the end of the study.
Severe hypoglycemia was defined as “an event associated with
severe neuroglycopenia usually resulting in coma or seizure and
requiring parenteral therapy (glucagon or intravenous glucose)”
(38). Severe hypoglycemic events were recorded both in the year
before and in the year following the switch from IGlar to IDeg.
In addition to the analyses on the overall population, patients
were divided into two groups according to baseline HbA1c values
(Group A ≤7.5%; Group B>7.5%) for further comparisons.
Statistical Analyses
Descriptive data are reported as mean± standard deviation (SD),
median, and range. Data were checked for normal distribution
using the Kolmogorov-Smirnov test. Longitudinal changes were
analyzed using the Friedman’s ANOVA for multiple dependent
samples, the Wilcoxon Matched Pairs Test for two dependent
samples, and McNemar’s test. Between-group comparisons were
performed using the Mann-Whitney’s U-test and the Pearson
χ2. Potential predictors of longitudinal changes in HbA1c
were evaluated using a multivariate regression model including
gender, age, duration of diabetes, baseline HbA1c, basal, and
bolus insulin dose before switching, percentage change in basal
insulin dose at the time of switching, and number of daily
insulin injections before switching. For each test, statistical
significance was considered for p < 0.05. Statistical analyses
were performed using the STATISTICA
TM
software (StatSoft Inc.,
Tulsa, OK, USA).
RESULTS
Patient Characteristics
This study presents data from 37 children and adolescents (22
males, 59.5%) with T1D, having age of 11.7± 4.22 years (median
12.7 years; range 3.1–17.9 years) and duration of diabetes of 4.97
± 3.63 years (median 4.3 years; range 1.0–14.4 years). Eighteen
patients (48.6%) were recruited because of HbA1c >7.5% (>58
mmol/mol), while 19 patients self-reported physical pain to IGlar
injection despite a good glycemic control. At the beginning of
the study, 51.3% of subjects were in a prepubertal status (Tanner
stage 1) and none started puberty during the 1-year follow-up.
All the other 18 patients were post-pubertal (Tanner stage 4–5).
Nine out 18 were females and all had menarche.
All patients received IDeg injection during the evening or
before bedtime and 8 patients received regular insulin injections
at breakfast and lunch while they used rapid-acting analog at
dinner. All other patients used a rapid-acting analog at MT. The
initial dose of IDeg ranged from 60 to 150% of the dose of IGlar
in 26 patients, while the initial dose of the bolus insulin was
not changed in 29. Baseline characteristics of study subjects are
reported in Table 1.
Glycemic Control
After switching to IDeg, despite the lack of statistical significance,
HbA1c median values decreased from 7.5% (58 mmol/mol) to
7.2% (55 mmol/mol) at T1 and 7.3% (56 mmol/mol) at both T2
and T3 (Table 1; Figure 1A). At T0, 19 out of 37 patients (51.4%)
had a good HbA1c level, while at T3 HbA1c values were on target
in 62.2% of the patients (Figure S1).
Mean FPG levels were not significantly decreased, but at T3
values resulted 3% lower compared to T0 (Table 1).
Glycemic control indexes at the beginning and at the end of
the study period were not different between subjects according
to pubertal status. Moreover, no significant longitudinal change
was demonstrated in both prepubertal and post-pubertal groups
(data not shown). Median HbA1c values at the end of the study
were 6.8% (51 mmol/mol) in prepubertal subjects and 7.4% (57
mmol/mol) in post-pubertal ones.
Insulin Requirement
The switch from IGlar to IDeg allowed a significant decrease of
the number of daily insulin injections from T0 to T3 (5.23± 1.18
vs. 4.89± 1.02, respectively; p= 0.002).
The insulin TDD was slightly lower during the IDeg
administration period than in the IGlar one, although the
difference did not reach statistical significance (p = 0.062).
Looking at IDeg and MT apart, a significant increase in the
IDeg dose (p < 0.001) and a significant decrease in MT insulin
dose (p = 0.001) (Table 1; Figures 1B,C, respectively) were
documented. At T3 the median IDeg dose increased by 12.5%,
while the medianMT insulin dose decreased by 11.6%.We found
that the distribution ratio of basal insulin dose with respect to the
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TABLE 1 | Characteristics of study population.
Characteristics Basal insulin switch IDeg follow-up χ2 p
IGlar T0 IDeg T0 T1 T2 T3
Puberty (Tanner 1/Tanner 4-5) 19/18 = = = = – –
HbA1c (%) 7.56 ± 1.04 (7.50) – 7.35 ± 0.97 (7.20) 7.43 ± 1.02 (7.30) 7.49 ± 1.15 (7.30) 1.50 0.682
HbA1c (mmol/mol) 59.1 ± 11.3 (58.5) 56.8 ± 10.6 (55.2) 57.7 ± 11.1 (56.3) 58.3 ± 12.5 (56.3)
HbA1c ≤7.5% (≤58mmol/mol) -
T0 vs. T1 19 (51.4%) - 20 (54.1%) 0.00 1.000
T0 vs. T2 19 (51.4%) - 22 (59.5%) 0.31 0.579
T0 vs. T3 19 (51.4%) 23 (62.2%) 0.90 0.343
Mean FPG (mg/dl) 168.5 ± 46.6 (163.0) – 161.8 ± 42.8 (152.5) 141.6 ± 21.3 (138.5) 143.8 ± 18.6 (143.0) 2.90 0.400
TDD insulin (IU/kg/day) 0.93 ± 0.26 (0.95) 0.90 ± 0.27 (0.94) 0.89 ± 0.25 (0.88) 0.89 ± 0.26 (0.90) 0.91 ± 0.23 (0.93) 8.97 0.062
Basal insulin (IU/kg/day) 0.38 ± 0.12 (0.36) 0.35 ± 0.12 (0.34) 0.39 ± 0.11 (0.36) 0.40 ± 0.11 (0.41) 0.42 ± 0.11 (0.42) 20.6 <0.001
MT insulin (IU/kg/day) 0.55 ± 0.21 (0.52) 0.55 ± 0.20 (0.52) 0.50 ± 0.19 (0.49) 0.49 ± 0.21 (0.50) 0.49 ± 0.19 (0.45) 17.5 0.001
Insulin injections (n/day) 5.23 ± 1.18 (5.50) – – – 4.89 ± 1.02 (4.00) – 0.002
Severe hypoglycemic events (n) 1/37 – 0/37 0/37 0/37 – –
BMI z-score (SDS) 0.41 ± 1.00 (0.33) – 0.39 ± 1.00 (0.49) 0.40 ± 0.98 (0.43) 0.40 ± 1.06 (0.65) 1.19 0.755
Bold values indicate statistically significant p < 0.05.
insulin TDD significantly increased from 41.4± 9.7% with IGlar
at T0 to 46.9± 11.8% with IDeg at T3 (p= 0.004).
When analyzing data according to pubertal status, we found
that TDD was always significantly higher in post-pubertal group
respect to prepubertal one, as expected (data not shown). Using
Friedman ANOVA we demonstrated a significant decrease of
TDD only in post-pubertal patients (χ2 =10.8; p = 0.029)
and this change was due to the significant reduction of MT
insulin dose (χ2 =14.1; p = 0.007). In prepubertal subjects
TDD was longitudinally unchanged, but the basal:bolus ratio was
changed because of IDeg dose significantly increased (χ2 =15.3;
p= 0.004).
Safety Data
One severe hypoglycemic event was reported before basal insulin
switching, while none occurred in the 1-year follow-up with IDeg
treatment.
No side effect was reported during the study period and
patients who had previously complained physical pain at IGlar
injection did not present this painful symptom using IDeg.
Finally, the BMI z-score remained unchanged after switching
to IDeg (Table 1).
Multiple Regression Analysis
Considering the whole study population, multivariate regression
analysis allowed us to identify HbA1c value at T0 as a predictor
of HbA1c change at T1 (β = −0.667, p = 0.001) and T2
(β = −0.681, p = 0.002); none of the variables tested predicted
HbA1c change at T3 (Table S1).
Subgroup Analysis According To HbA1c
Group
Patient Characteristics
The statistical analysis was also performed subdividing the study
population into 2 groups:
A. HbA1c ≤7.5% (≤58 mmol/mol) including 19 patients (12
males, 63.1%) aged 10.2 ± 4.04 years (median 8.70 years;
range 3.60-17.1 years) and duration of diabetes of 4.56± 3.98
years (median 2.70 years; range 1.10–14.4 years); 12 (63.1%)
in prepubertal status.
B. HbA1c >7.5% (>58 mmol/mol) including 18 patients (10
males, 55.5%) aged 13.3 ± 3.87 years (median 13.9 years;
range 3.1–17.9 years) and duration of diabetes of 5.41 ± 3.27
years (median 5.25 years; range 1.0–12.0 years); 7 (38.9%) in
prepubertal status.
Baseline characteristics of each group are reported in Table 2.
Despite patients included in Group A were significantly younger
than those in Group B (p = 0.013) the duration of diabetes was
not different (p= 0.267).
Glycemic Control
As expected, Group A showed significantly lower levels of HbA1c
compared to Group B at T0 and throughout the study period
(Table 2). After the switch from IGlar to IDeg, 11 patients of
Group B (61.1%) improved their HbA1c values and 7 (38.9%)
reached HbA1c levels ≤7.5% (≤58 mmol/mol) at T3. In Group
A, 16 patients (84.2%) kept HbA1c ≤7.5% at T3 (Figure S1). As
compared to T0, HbA1c was unchanged after switching to IDeg
in both groups. In Group B, we found a decrease in HbA1c values
from 8.46 ± 0.53% (68.9 ± 5.8 mmol/mol) to 7.89 ± ± 0.72%
(62.7 ± 7.9 mmol/mol) at T1 (p = 0.008), 7.97 ± 0.89% at T2
(63.6 ± 9.8 mmol/mol) (p = 0.035), and 8.12 ± 1.13% (65.3 ±
12.4 mmol/mol) at T3 (p= 0.136; Figure S2).
Mean FPG values were also significantly lower in Group
A compared to Group B (Table 2). In Group B, mean FPG
levels significantly decreased from 204.5 ± 52.5 mg/dl at T0 to
153.2 ± 28.6 mg/dl at T2 (p = 0.043; Figure S2), with percent
decreases of mean FPG values of −10.4% at T1, −18.2% at T2,
and−8.26% at T3.
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FIGURE 1 | Changes of HbA1c (A), basal insulin dose (B), and MT insulin
dose (C) in the study population after the switch from IGlar to IDeg. (A) HbA1c
(%) (χ2 =1.50; p = 0.682). (B) Basal insulin dose (IU/kg/day) (χ2 = 20.6; p <
0.001). (C) MT insulin dose (IU/kg/day) (χ2 = 17.5; p = 0.001).
Insulin Requirement
Throughout the study period, Group A patients did more daily
insulin injections than those in Group B. The switch from IGlar
to IDeg allowed a statistical significant decreased in the number
of injections at the end of follow-up only in Group A (p = 0.012;
Table 2).
Insulin doses were never significantly different between
analyzed groups. After switching to IDeg, insulin TDD remained
unchanged in both groups. Looking at basal insulin and MT
apart, we documented a significant increase of IDeg dose in
both Group A and Group B (p = 0.026 and p = 0.042,
respectively), while a significant decrease of MT insulin dose
was found only in Group A (p = 0.020; Table 2). Specifically,
at T3, the IDeg dose increased by 13.4% in Group A and
8.3% in Group B. The MT insulin dose was decreased by
12.7% in Group A and 7.9% in Group B. The distribution
ratio of basal insulin respect to insulin TDD was not different
between Group A and Group B both at T0 (IGlar T0: 42.4
± 8.54 vs. 40.2 ± 10.8%, respectively; p = 0.438) and at
T3 (IDeg T3: 49.9 ± 13.4 vs. 43.8 ± 9.36%, respectively;
p= 0.438).
Safety Data
The only severe hypoglycemic event during IGlar treatment
was reported by a patient belonging to Group A. No severe
hypoglycemic event occurred in the 1-year follow-up with IDeg
in both groups.
After switching to IDeg, the BMI z-score remained unchanged
in both groups (Table 2).
DISCUSSION
In this study, children and adolescents outpatients with T1D
whose once-daily IGlar was switched to once-daily IDeg were
observed for 1-year. Our data provide a better understanding on
how to change both basal and bolus insulin doses when switching
from IGlar to IDeg and how these therapeutic changes can impact
on glycemic control, in a real-world pediatric clinical practice.
Despite IDeg pharmacokinetic profile seen in adults was
shown also in children and adolescents with T1D (31), to the best
of our knowledge only one published study compared its efficacy
and safety with respect to IGlar in this age group (33).
Appropriate basal and bolus insulin dosages need be adjusted
when switching to IDeg; we found a significant increase in
IDeg dose (+12.5%) compared to IGlar dose and a significant
reduction in MT insulin doses (−11.6%). The increase in IDeg
dose is at variance with a published study on adults with T1D,
where mean doses of basal and pre-meal bolus insulin were
significantly decreased by 14% and 10% in the IDeg group
compared with the IGlar group (22). It was suggested that
appropriate replacement IDeg doses should be lowered by 10–
20% for patients who previously received once-daily injection
of IGlar and by 20–30% for those previously given twice-daily
injections (39). Based on our data, more studies are needed to
verify what is the best way to switch from IGlar to IDeg in
pediatric population.
Despite precise recommendations cannot be made on the
basis of our data, we demonstrated that the mean final ratio of
IDeg was 50% of the insulin TDD, suggesting that this probably
should be the optimal starting IDeg dose in a basal-bolus
treatment to obtain a good glycemic control. According to ISPAD
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TABLE 2 | Characteristics of patients according to HbA1c group.
Characteristics Study time Group p
A. HbA1c ≤7.5% (≤ 58
mmol/mol)
B. HbA1c >7.5% (> 58
mmol/mol)
Subjects (n) IGlar/IDeg T0 19 18 –
Gender (Male/Female) IGlar/IDeg T0 12/7 10/8 0.638
Age (years) IGlar/IDeg T0 10.2 ± 4.04 (8.70) 13.3 ± 3.87 (13.9) 0.013
Duration of diabetes (years) IGlar/IDeg T0 4.56 ± 3.98 (2.70) 5.41 ± 3.27 (5.25) 0.267
Puberty (No/Yes) IGlar/IDeg T0 12/7 7/11 0.139
HbA1c (%)
(mmol/mol)
IGlar/IDeg T0
T1
T2
T3
6.71 ± 0.55 (6.80)
49.8 ± 6.0 (50.8)
6.83 ± 0.90 (6.70)
51.2 ± 9.8 (49.7)
6.92 ± 0.87 (6.70)
52.1 ± 9.5 (49.7)
6.88 ± 0.78 (6.60)
51.7 ± 8.6 (48.6)
χ
2 = 5.41; p = 0.144
8.46 ± 0.53 (8.50)
68.9 ± 5.8 (69.4)
7.89 ± 0.72 (7.85)
62.7 ± 7.9 (62.3)
7.97 ± 0.89 (7.80)
63.6 ± 9.8 (61.7)
8.12 ± 1.13 (7.70)
65.3 ± 12.4 (60.6)
χ
2 = 5.28; p = 0.152
<0.001
0.001
0.002
0.001
Mean FPG (mg/dl) IGlar/IDeg T0
T1
T2
T3
145.3 ± 22.1 (141.5)
141.5 ± 17.5 (137.0)
136.7 ± 16.3 (132.5)
138.6 ± 17.7 (137.0)
χ
2 = 0.64; p = 0.888
204.5 ± 52.7 (195.0)
191.1 ± 52.1 (186.0)
153.2 ± 28.6 (152.5)
160.5 ± 10.3 (158.0)
χ
2 = 4.66; p = 0.199
0.001
0.011
0.201
0.042
TDD insulin (IU/kg/day) IGlar T0
IDeg T0
T1
T2
T3
0.86 ± 0.25 (0.85)
0.84 ± 0.25 (0.83)
0.83 ± 0.23 (0.78)
0.83 ± 0.21 (0.85)
0.85 ± 0.21 (0.83)
χ
2 = 4.49; p = 0.343
1.00 ± 0.26 (1.00)
0.97 ± 0.28 (0.99)
0.95 ± 0.27 (0.92)
0.95 ± 0.29 (0.95)
0.98 ± 0.23 (0.98)
χ
2 = 5.46; p = 0.243
0.186
0.098
0.242
0.230
0.118
Basal insulin (IU/kg/day) IGlar T0
IDeg T0
T1
T2
T3
0.36 ± 0.13 (0.35)
0.33 ± 0.14 (0.31)
0.38 ± 0.13 (0.35)
0.40 ± 0.13 (0.38)
0.41 ± 0.12 (0.42)
χ
2
= 11.1; p = 0.026
0.39 ± 0.11 (0.40)
0.37 ± 0.10 (0.40)
0.40 ± 0.09 (0.40)
0.40 ± 0.10 (0.42)
0.42 ± 0.09 (0.43)
χ
2
= 9.93; p = 0.042
0.403
0.176
0.370
0.750
0.843
MT insulin (IU/kg/day) IGlar T0
IDeg T0
T1
T2
T3
0.50 ± 0.17 (0.47)
0.50 ± 0.17 (0.47)
0.45 ± 0.16 (0.42)
0.43 ± 0.17 (0.42)
0.43 ± 0.18 (0.40)
χ
2
= 11.7; p = 0.020
0.61 ± 0.23 (0.58)
0.60 ± 0.22 (0.60)
0.55 ± 0.20 (0.52)
0.55 ± 0.23 (0.54)
0.56 ± 0.19 (0.57)
χ
2 = 7.11; p = 0.130
0.062
0.104
0.095
0.158
0.058
Insulin injections (n/day) IGlar/IDeg T0
T3
5.66 ± 1.20 (6.00)
5.26 ± 1.04 (6.00)
p = 0.012
4.78 ± 0.99 (4.00)
4.50 ± 0.86 (4.00)
p = 0.068
0.023
0.043
Severe hypoglycemic events (n) IGlar/IDeg T0
T1
T2
T3
1/19
0/19
0/19
0/19
0/18
0/18
0/18
0/18
–
–
–
–
BMI z-score (SDS) IGlar/IDeg T0
T1
T2
T3
0.39 ± 0.99 (0.32)
0.34 ± 1.06 (0.49)
0.41 ± 1.05 (0.60)
0.41 ± 1.11 (0.80)
χ
2 = 7.47; p = 0.058
0.43 ± 1.05 (0.39)
0.44 ± 0.96 (0.43)
0.38 ± 0.94 (0.40)
0.40 ± 1.04 (0.63)
χ
2 = 2.47; p = 0.481
0.939
0.976
0.750
0.704
Bold values indicate statistically significant p < 0.05.
recommendations, in multiple daily insulin injections therapy,
40–60% of the insulin TDD should be given as a long-acting
analog (6).
However, our results should be also interpreted considering
that both early and mid pubertal patients were not included in
the population study avoiding data associated with the worst
insulin resistance and the necessary increase of TDD (6). Basal
insulin dose for T1D treated with multiple daily injections
should be modified according to patient age and pubertal
status. Subjects having an age between 10 and <20 years were
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demonstrated to have a significantly higher percentage of basal
insulin dose than both younger and older ones (40). We found
that basal insulin dose was not different between pre-pubertal
and post-pubertal patients, but during 1-year follow-up it was
significantly increased in prepubertal group but not in the post-
pubertal ones. Considering also the metabolic control obtained
by our post-pubertal patients, we hypothesize that we should
consider the possibility to increase more the IDeg dose even in
these patients, without taking into consideration data provided
by clinical trials in adults.
In our study population, HbA1c and mean FPG
concentrations were unchanged after switching to IDeg. In
children with HbA1c ≤7.5% at baseline, the 1-year switching
to IDeg had no effect on both HbA1c (+0.10%) and mean FPG
values (−2.7%), making questionable the usefulness of changing
an insulin therapy that has already allowed a good glycemic
control. On the other hand, these patients were switched to
IDeg because of self-reported physical pain at IGlar injection,
which was not referred during follow-up. This aspect is probably
important for a better quality of life. Benefits were instead noted
in the group of patients with high basal HbA1c levels, both
in terms of HbA1c and mean FPG. At 1-year follow-up, in
these patients HbA1c decreased by 0.55% point with IDeg, in
agreement with data in adults with T1D, and mean FPG levels
decreased by 18.2% after 6 months and 8.3% at 1-year follow-up.
Reaching the HbA1c goal is important to avoid the long-
term microvascular and macrovascular complications of T1D
while also avoiding acute complication such as hypoglycemia.
Moreover, at the end of our study, 62.2% of all patients had
HbA1c values at target, as compared to 43% in adults (22).
This is the first report showing in children and adolescents
with T1D that baseline HbA1c was a significant predictor of
change in HbA1c when switching from IGlar to IDeg. Larger
decreases in HbA1c with higher baseline HbA1c were previously
demonstrated in adults (41). To attain these results on glycemic
control insulin doses were personalized as possible and adjusted
according to individual needs. However, some of the poorly
controlled patients experienced no improvement in HbA1c
levels after IDeg, suggesting that switching to a new insulin by
itself does not necessarily improve glucose control.
The switch from IGlar to IDeg in our patients allowed a
significant reduction of the number of daily insulin injections
at the end of follow-up. These findings, already reported in
adults with T1D (29), are important considering that insulin
effectiveness can be reduced by several factors related to patients’
practices in taking their daily dose.
No severe hypoglycemic episode was documented in our
study after switching from IGlar to IDeg. Nevertheless,
despite we can exclude problems with underreporting for
the severe hypoglycemia, milder symptomatic hypoglycemia
was not assessed. In children it was demonstrated that no
severe hypoglycemia occurred with both IGlar and IDeg, but
nocturnal hypoglycemia significantly decreased only with IDeg
use (33).
Strengths of our study include the long follow-up time and
the use of real-life data, which are more representative of the
outpatient population than those included in clinical trials.
However, this study has limitations such as the retrospective,
non-randomized nature of the design study. First of all, a control
group was not included. However, we believe that our patients
with their baseline features, recorded before the switch from
IGlar to IDeg, could be considered as control of themselves.
Our main outcome was to evaluate the efficacy and safety of
IDeg in a population that was previously in therapy with IGlar,
comparing metabolic and therapeutic data before and after the
switch. Being patients the same before and after the basal insulin
switch, probably we avoided the bias of different individual ability
to manage therapeutic and metabolic control due to different
understanding of therapeutic education and adaptation to T1D.
Secondly, we recruited only pre- and post-pubertal subjects. We
should take into consideration that insulin daily requirement is
different between pre-puberty and different stages of pubertal
development, during which TDD gradually rise. The correct dose
of insulin is the one which achieves the best attainable glycemic
control for an individual child or adolescent without causing
obvious hypoglycemia problems. So, insulin dosesmust be always
personalized as possible and adjusted according to individual
needs, including pubertal status. Third aspect to be considered is
that the decision to switch to IDeg based on HbA1c levels≤7.5%
(≤58mmol/mol) accounts for the 51.4% of our study population,
with a possible bias toward selecting patients with a good
compliance having already a good glycemic control. Moreover,
insulin titration was performed according to routine clinical
practice without reference to a pre-specified algorithm, thus
potentially increasing heterogeneity. Finally, daily blood glucose
levels were measured using portable glucometers. Although
patients and parents were well trained and had already used these
glucose meters for some years before enrollment, possible errors
and failures in measuring and recording blood glucose levels
could have occurred. Despite these limitations, our results are
peculiar and innovative with respect to adult experience and the
follow-up is sufficiently long to avoid influences by the period of
titration of IDeg.
In conclusion, in our real-world clinical practice switching
to IDeg resulted effective and safe in children and adolescents
with T1D. On the basis of our experience the IDeg dose
should be increased by 12.5% and MT replacement doses
should be reduced by 11.6% in patients who previously received
IGlar. The basal:bolus ratio 50:50 seems to be appropriate to
obtain a reduction in the number of insulin injections and
an improvement of glycemic control without increasing the
risk for severe hypoglycemic events. IDeg may represent an
ultra-long-acting analog alternative to IGlar for patients with
a poor glycemic control and/or with physical pain at IGlar
injection.
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